Amarin names Huff to lead cholesterol drug commercialization

Thu, 02/03/2011 - 4:35am
Mass High Tech: The Journal of New England Technology

Amarin Corp. plc, an Irish biotech with U.S. research and development headquarters in Mystic, Conn., has named Paul Huff, an industry veteran with cholesterol drug commercialization under his belt, as chief commercial officer. He will be in charge of leading the company's commercialization plan for its AMR101 cholesterol drug, aimed at lowering high triglyceride levels. The appointment coincides with Amarin's announcement of plans to open a U.S. sales and marketing headquarters in New Jersey, separate from the R&D headquarters in Connecticut.

Huff joins Amarin having served previously as vice president of marketing for Reliant Pharmaceuticals Inc., where he helped commercialize the company's Lovaza drug made for reducing triglycerides. A similar position at Kos Pharmaceuticals Inc. had Huff helping to commercialize another cholesterol drug, called Niaspan, developed to help raise HDL cholesterol.




Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.